{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:39:38Z","timestamp":1791092378866,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1124\/jpet.109.158113","type":"journal-article","created":{"date-parts":[[2009,11,26]],"date-time":"2009-11-26T00:08:08Z","timestamp":1259194088000},"page":"1072-1080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats"],"prefix":"10.1016","volume":"332","author":[{"given":"Akira","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kobori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isseki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naro","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.109.158113_bib1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00004872-200103000-00015","article-title":"Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril","volume":"19","author":"Balt","year":"2001","journal-title":"J Hypertens"},{"key":"10.1124\/jpet.109.158113_bib2","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/j.1523-1755.2004.00636.x","article-title":"Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy","volume":"65","author":"Benigni","year":"2004","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.109.158113_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.109.158113_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.106.179294","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"115","author":"Buse","year":"2007","journal-title":"Circulation"},{"key":"10.1124\/jpet.109.158113_bib5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.109.158113_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1527-3466.2001.tb00064.x","article-title":"Eplerenone: a selective aldosterone receptor antagonist (SARA)","volume":"19","author":"Delyani","year":"2001","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1124\/jpet.109.158113_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199807093390202","article-title":"Reversal of lesions of diabetic nephropathy after pancreas transplantation","volume":"339","author":"Fioretto","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.109.158113_bib8","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.109.158113_bib9","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/01.ASN.0000127988.42710.A7","article-title":"Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats","volume":"15","author":"Hoffmann","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.109.158113_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ki.2008.128","article-title":"Proteinuria in diabetic kidney disease: a mechanistic viewpoint","volume":"74","author":"Jefferson","year":"2008","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.109.158113_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfn448","article-title":"Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats","volume":"24","author":"Kang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.109.158113_bib12","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1046\/j.1523-1755.2000.00044.x","article-title":"Cloning of rat nephrin: expression in developing glomeruli and in proteinuric states","volume":"57","author":"Kawachi","year":"2000","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.109.158113_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1254\/jphs.08R02CR","article-title":"Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury","volume":"108","author":"Kiyomoto","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.109.158113_bib14","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1681\/ASN.2004080676","article-title":"Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats","volume":"16","author":"Kobori","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.109.158113_bib15","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/01.ASN.0000078803.53165.C9","article-title":"Expression of podocyte-associated molecules in acquired human kidney diseases","volume":"14","author":"Koop","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.109.158113_bib16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1124\/jpet.109.158113_bib17","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1161\/01.CIR.0000131860.80444.AB","article-title":"Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells","volume":"109","author":"Mazak","year":"2004","journal-title":"Circulation"},{"key":"10.1124\/jpet.109.158113_bib18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/ATVBAHA.108.168021","article-title":"Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways","volume":"28","author":"Montezano","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/jpet.109.158113_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1681\/ASN.2004080649","article-title":"Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats","volume":"16","author":"Nagai","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.109.158113_bib20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker","volume":"47","author":"Nagase","year":"2006","journal-title":"Hypertension"},{"key":"10.1124\/jpet.109.158113_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jsbmb.2005.03.005","article-title":"Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL)","volume":"96","author":"Nishikawa","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/jpet.109.158113_bib22","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1097\/HJH.0b013e3283060efa","article-title":"Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria","volume":"26","author":"Nishiyama","year":"2008","journal-title":"J Hypertens"},{"key":"10.1124\/jpet.109.158113_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","article-title":"Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats","volume":"43","author":"Nishiyama","year":"2004","journal-title":"Hypertension"},{"key":"10.1124\/jpet.109.158113_bib24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1291\/hypres.30.325","article-title":"Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy","volume":"30","author":"Ogawa","year":"2007","journal-title":"Hypertens Res"},{"key":"10.1124\/jpet.109.158113_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/hr.2009.34","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)","volume":"32","author":"Ogihara","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1124\/jpet.109.158113_bib26","doi-asserted-by":"crossref","first-page":"F137","DOI":"10.1152\/ajprenal.00065.2008","article-title":"Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination","volume":"295","author":"Piecha","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.109.158113_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"10.1124\/jpet.109.158113_bib28","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s00125-005-1937-6","article-title":"Remission of nephrotic- range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients","volume":"48","author":"Rossing","year":"2005","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.109.158113_bib29","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2337\/diacare.25.11.1909","article-title":"Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study","volume":"25","author":"Sasso","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.109.158113_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1124\/jpet.109.158113_bib31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1124\/jpet.109.158113_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease","volume":"18","author":"Sato","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1124\/jpet.109.158113_bib33","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/sj.ki.5000410","article-title":"The podocyte's response to injury: role in proteinuria and glomerulosclerosis","volume":"69","author":"Shankland","year":"2006","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.109.158113_bib34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension"},{"key":"10.1124\/jpet.109.158113_bib35","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"10.1124\/jpet.109.158113_bib36","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1523-1755.2004.00576.x","article-title":"BMK1 is activated in glomeruli of diabetic rats and in mesangial cells by high glucose conditions","volume":"65","author":"Suzaki","year":"2004","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.109.158113_bib37","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2353\/ajpath.2007.060484","article-title":"Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall","volume":"170","author":"Suzuki","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.109.158113_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.109.158113_bib39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1476-5381.1993.tb13800.x","article-title":"Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277","volume":"110","author":"Wienen","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.109.158113_bib40","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/diabetes.54.6.1626","article-title":"From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy","volume":"54","author":"Wolf","year":"2005","journal-title":"Diabetes"},{"key":"10.1124\/jpet.109.158113_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/01.HYP.0000175814.18550.c0","article-title":"Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor","volume":"46","author":"Xue","year":"2005","journal-title":"Hypertension"},{"key":"10.1124\/jpet.109.158113_bib42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/10641960701578444","article-title":"Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism","volume":"29","author":"Younis","year":"2007","journal-title":"Clin Exp Hypertens"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524457029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524457029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.109.158113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:07:14Z","timestamp":1739999234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524457029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0022356524457029"],"URL":"https:\/\/doi.org\/10.1124\/jpet.109.158113","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.109.158113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}